{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:19:22Z","timestamp":1765808362030},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2024,5,10]]},"DOI":"10.1038\/s41415-024-7340-9","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T09:01:51Z","timestamp":1715331711000},"page":"683-687","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical status of established MRONJ in oncology patients continuing bone-modifying agents"],"prefix":"10.1038","volume":"236","author":[{"given":"Elizabeth","family":"Miles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sproat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"7340_CR5214","doi-asserted-by":"crossref","unstructured":"Henry D H, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"7340_CR5216","doi-asserted-by":"crossref","unstructured":"Yarom N, Shapiro C L, Peterson D E et al. Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37: 2270-2290.","DOI":"10.1200\/JCO.19.01186"},{"key":"7340_CR5218","unstructured":"UK Chemotherapy Board. Medication-related osteonecrosis of the jaw: guidance for the oncology multidisciplinary team. 2019. Available at https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/medication-related-osteonecrosis-jaw-guidance-oncology-multidisciplinary-team (accessed August 2023)."},{"key":"7340_CR5221","doi-asserted-by":"crossref","unstructured":"Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig 2018; 22: 597-615.","DOI":"10.1007\/s00784-017-2325-6"},{"key":"7340_CR5224","doi-asserted-by":"crossref","unstructured":"Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review. Heliyon 2020; 27: e03795.","DOI":"10.1016\/j.heliyon.2020.e03795"},{"key":"7340_CR5226","doi-asserted-by":"crossref","unstructured":"Otsuru M, Soutome S, Omori K et al. Relationship between drug holidays of antiresorptive agents and surgical outcomes in cancer patients with medication-related osteonecrosis of the jaw. Int J Environ Res Public Health 2022; 19: 4624.","DOI":"10.3390\/ijerph19084624"},{"key":"7340_CR5228","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Aghaloo T, Carlson E, Ward B B, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws - 2022 Update. J Oral Maxillofac Surg 2022; 80: 920-943.","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"7340_CR5230","doi-asserted-by":"crossref","unstructured":"Nicolatou-Galitis O, Papadopoulou E, Vardas E et al. Alveolar bone histological necrosis observed before extractions in patients, who received bone-targeting agents. Oral Dis 2020; 26: 955-966.","DOI":"10.1111\/odi.13294"},{"key":"7340_CR5233","doi-asserted-by":"crossref","unstructured":"King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab - a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127: 289-299.","DOI":"10.1016\/j.oooo.2018.11.012"},{"key":"7340_CR5235","doi-asserted-by":"crossref","unstructured":"Zebic L, Patel V. Preventing medication-related osteonecrosis of the jaw. BMJ 2019; DOI: 10.1136\/bmj.l1733.","DOI":"10.1136\/bmj.l1733"},{"key":"7340_CR5237","doi-asserted-by":"crossref","unstructured":"McLeod N M, Patel V, Kusanale A, Rogers S N, Brennan P A. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg 2011; 49: 335-342.","DOI":"10.1016\/j.bjoms.2010.08.005"},{"key":"7340_CR5239","doi-asserted-by":"crossref","unstructured":"Patel S, Patel N, Sassoon I, Patel V. The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws. Radiother Oncol 2021; 156: 209-216.","DOI":"10.1016\/j.radonc.2020.12.027"},{"key":"7340_CR5241","doi-asserted-by":"crossref","unstructured":"Otto S, Tr\u00f6ltzsch M, Jambrovic V et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 2015; 43: 847-854.","DOI":"10.1016\/j.jcms.2015.03.039"},{"key":"7340_CR5244","doi-asserted-by":"crossref","unstructured":"Ristow O, R\u00fcckschlo\u03b2 T, Moratin J et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake - a randomized pilot trial. Oral Dis 2021; 27: 532-546.","DOI":"10.1111\/odi.13556"},{"key":"7340_CR5246","doi-asserted-by":"crossref","unstructured":"Bedogni A, Blandamura S, Lokmic Z et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 358-364.","DOI":"10.1016\/j.tripleo.2007.08.040"},{"key":"7340_CR5248","doi-asserted-by":"crossref","unstructured":"Matharu J, Taylor H, Sproat C, Kwok J, Brown J, Patel V. Diffuse sclerosing osteomyelitis: a case series and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; 129: 437-446.","DOI":"10.1016\/j.oooo.2019.11.010"},{"key":"7340_CR5250","doi-asserted-by":"crossref","unstructured":"Mahendran K, Wali R, Patel V. Sickle cell osteomyelitis: a novel approach and review of the literature. Oral Surg 2021; 14: 365-370.","DOI":"10.1111\/ors.12587"},{"key":"7340_CR5253","doi-asserted-by":"crossref","unstructured":"Cheng H, Wali R, Sproat C, Patel V. Secondary chronic osteomyelitis of the mandible: A resistant disease successfully treated with bisphosphonate therapy. Oral Surg 2021; 14: 259-264.","DOI":"10.1111\/ors.12578"},{"key":"7340_CR5255","doi-asserted-by":"crossref","unstructured":"Ottesen C, Schiodt M, Jensen S S, Kofod T, Gotfredsen K. Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation. Oral Surg Oral Med Oral Pathol Oral Radiol 2022; 133: 165-173.","DOI":"10.1016\/j.oooo.2021.06.003"},{"key":"7340_CR5257","doi-asserted-by":"crossref","unstructured":"Hamid A, Thomas S, Bell C, Gormley M. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday. Br J Oral Maxillofac Surg 2023; 61: 227-232.","DOI":"10.1016\/j.bjoms.2023.02.003"},{"key":"7340_CR5260","doi-asserted-by":"crossref","unstructured":"Coleman R, Hadji P, Body J-J et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31: 1650-1663.","DOI":"10.1016\/j.annonc.2020.07.019"},{"key":"7340_CR5263","doi-asserted-by":"crossref","unstructured":"Rosen L S, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumours: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumours Study Group. J Clin Oncol 2003; 21: 3150-3157.","DOI":"10.1200\/JCO.2003.04.105"},{"key":"7340_CR5265","doi-asserted-by":"crossref","unstructured":"Gnant M, Pfeiler G, Dubsky P C et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 433-443.","DOI":"10.1016\/S0140-6736(15)60995-3"},{"key":"7340_CR5267","doi-asserted-by":"crossref","unstructured":"Smith M R, McGovern F J, Zietman A L et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.","DOI":"10.1056\/NEJMoa010845"},{"key":"7340_CR5270","doi-asserted-by":"crossref","unstructured":"Djulbegovic B, Wheatley K, Ross H et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2001; DOI: 10.1002\/14651858.CD003188.","DOI":"10.1002\/14651858.CD003188"},{"key":"7340_CR5272","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353-1361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"7340_CR5274","doi-asserted-by":"crossref","unstructured":"Morgan G J, Davies F E, Gregory W M et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999.","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"7340_CR5277","doi-asserted-by":"crossref","unstructured":"Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008; 16: 879-889.","DOI":"10.1007\/s00520-008-0418-0"},{"key":"7340_CR5280","doi-asserted-by":"crossref","unstructured":"Pockett R D, Castellano D, Mcewan P, Oglesby A, Barber B L, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010; 19: 755-760.","DOI":"10.1111\/j.1365-2354.2009.01135.x"},{"key":"7340_CR5282","doi-asserted-by":"crossref","unstructured":"Von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body J-J. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev 2019; 76: 57-67.","DOI":"10.1016\/j.ctrv.2019.05.003"},{"key":"7340_CR5285","doi-asserted-by":"crossref","unstructured":"Coleman R E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; DOI: 10.1158\/1078-0432.CCR-06-0931.","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"7340_CR5287","doi-asserted-by":"crossref","unstructured":"Patel V, Wali R, Burns M et al. The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer. Br Dent J 2022; 232: 95-100.","DOI":"10.1038\/s41415-022-3875-9"},{"key":"7340_CR5290","doi-asserted-by":"crossref","unstructured":"D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol 2019; 15: 100205.","DOI":"10.1016\/j.jbo.2018.10.004"},{"key":"7340_CR5292","doi-asserted-by":"crossref","unstructured":"Yang M, Yu X. Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. Support Care Cancer 2020; 28: 2533-2540.","DOI":"10.1007\/s00520-020-05355-7"},{"key":"7340_CR5294","doi-asserted-by":"crossref","unstructured":"Cummings S R, Ferrari S, Eastell R et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018; 33: 190-198.","DOI":"10.1002\/jbmr.3337"},{"key":"7340_CR5296","doi-asserted-by":"crossref","unstructured":"Stewart A F. Clinical practice. Hypercalcaemia associated with cancer. N Engl J Med 2005; 352: 373-379.","DOI":"10.1056\/NEJMcp042806"},{"key":"7340_CR5299","doi-asserted-by":"crossref","unstructured":"Ralston S H, Gallacher S J, Patel U, Campbell J, Boyle I T. Cancer-associated hypercalcaemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990; 112: 499-504.","DOI":"10.7326\/0003-4819-112-7-499"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7340-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7340-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7340-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T09:03:15Z","timestamp":1715331795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7340-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,10]]}},"alternative-id":["7340"],"URL":"https:\/\/doi.org\/10.1038\/s41415-024-7340-9","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"15 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Ethical approval and consent was not applicable for this retrospective clinical evaluation of historic practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Data availability","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Not applicable (clinical outcome reporting and sensitive nature of the data).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}